Prostate cancer is a common disease in men. The diagnosis is usually established using blood tests, MRI scans, and tissue biopsies. With the development of new treatment options, care is becoming increasingly personalized. This also calls for better ways to monitor the disease and assess how well treatments are working. This thesis investigates how liquid biopsies, which analyze circulating biomarkers, can support this. It also describes a specific RNA molecule, NAALADL2-AS2, that is associated with hormone resistance in treatment-naïve prostate cancer. In addition, the thesis shows that analyzing gene expression in circulating tumor cells can provide valuable insights into disease progression and response to treatment. Overall, the results suggest that liquid biopsies can be an important complement to current diagnostic approaches.
Molecular biologist and data scientist specialized stratifying clinical outcomes through characterization of molecular resistance pathways in advanced prostate cancer. Extensive experience in academic and applied clinical research, biomarker discovery, and transcriptomics. Applies scientific expertise and analytical skills to identify novel opportunities in biotech.